Opendata, web and dolomites

Soraprazan SIGNED

Soraprazan - a new regenerative therapy for Stargardt's disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Soraprazan" data sheet

The following table provides information about the project.

Coordinator
EBERHARD KARLS UNIVERSITAET TUEBINGEN 

Organization address
address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074
website: www.uni-tuebingen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 5˙792˙425 €
 EC max contribution 5˙792˙425 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) coordinator 467˙500.00
2    KATAIRO GMBH DE (KUSTERDINGEN) participant 2˙705˙000.00
3    SMERUD MEDICAL RESEARCH INTERNATIONAL AS NO (OSLO) participant 1˙561˙250.00
4    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 319˙500.00
5    UNIVERSITY OF SOUTHAMPTON UK (SOUTHAMPTON) participant 252˙500.00
6    OSPEDALE SAN RAFFAELE SRL IT (MILANO) participant 180˙171.00
7    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 178˙222.00
8    UNIVERSITATSKLINIKUM BONN DE (BONN) participant 128˙281.00

Map

 Project objective

Soraprazan – a new regenerative therapy for Stargardt’s disease Abnormal accumulation of lipofuscin in the RPE cells is a hallmark in Stargardt's disease. As lipofuscin cannot be removed from the RPE cells in the eyes neither spontaneously nor with existing therapies, the accumulation of lipofuscin in the RPE cells of the eyes results in the degradation of the RPE cells and consequently in worsening of visual acuity and could lead to blindness. Soraprazan was able to show removal of lipofuscin in RPE cells. Aim of the phase II trial in this project is to evaluate savety and efficacy or orally taken Soraprazan treatment compared to placebo.

 Deliverables

List of deliverables.
Project Website Websites, patent fillings, videos etc. 2020-02-18 10:37:48

Take a look to the deliverables list in detail:  detailed list of Soraprazan deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SORAPRAZAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SORAPRAZAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More